ARCHIVES

The Meeting Worth Lobbying For: A “PRG” For Disease-Specific Review; NCI Plans Six.

This article is from The Cancer Letter archive.

Vol. 26 No. 25 | June 23, 2000

Download PDF Visit The Full Archive

Related Articles

Study Finds High-Risk Women Reluctant To Take Tamoxifen

December 25, 2009

Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic

May 30, 2014

Change In Method Of Counting Cancer Incidence Results In More Attributed To Work Hazards

October 6, 1978

WHO Names Brinker As Goodwill Ambassador

May 29, 2009

NCI Programs: Advisors Approve concept For Spiral CT Image Database Consortium

November 12, 1999

DeLap: Seven Years In industry Provided View Of Pressures On Drug Developers

August 2, 1996